Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
- Documented BRCA1/2 mutation AND a BRCA-related malignancy (e.g., primarily
breast or ovarian cancer, but may include prostate or pancreatic cancer) or triple-
negative breast cancer. Progressive disease after standard therapy OR no acceptable standard treatment options available.
- Platinum-refractory ovarian, fallopian tube, or primary peritoneal cancer
- Patients with platinum-sensitive disease must have known BRCA mutations
- Basal-like breast cancer, defined as estrogen and progesterone receptor-negative, HER2-negative, and/or expression profile of EGFR and cytokeratins 5/6 consistent with basal phenotype
"Triple-negative" phenotype (i.e., negative hormone and HER2 receptors) allowed
Type of study:
- Patients receive oral ABT-888 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or toxicity.
City of Hope
Contact: Robert J. Morgan 626-256-4673 firstname.lastname@example.org
University of Southern California
Contact: Agustin A. Garcia 323-865-0832 email@example.com
UC Davis Comprehensive Cancer Center
Contact: David R. Gandara 916-734-3772 firstname.lastname@example.org
City of Hope - South Pasadena
Contact: Stephen C. Koehler 626-396-2900 Skoehler@cohmg.com
Cancer Institute of New Jersey
Contact: Antoinette R. Tan 732-235-6777 email@example.com
Penn State Milton S Hershey Medical CenterPennsylvania
Contact: Chandra P. Belani 717-531-1078 firstname.lastname@example.org
UPMC Cancer Center
Contact: Clinical Trials Office - UPMC Cancer Centers 412-647-8073
Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.
This site has been made possible by a generous grant from Morphotek.